UPCC 10219: Phase II Study Of Stromal Changes Detected By DCE- and DW-MRI In Response To PEGPH20 Combined With Chemotherapy In Subjects With Locally-Advanced Pancreatic Cancer

Brief description of study

The research study is being conducted to determine the effects of PEGPH20 plus chemotherapy treatment on the MRI characteristics of pancreatic cancer tumors. Subjects will receive Gemcitabine, Abraxane, and PEGPH20.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    pancreatic cancer
  • Age: - 99 Years
  • Gender: All
Updated on 05 Dec 2019. Study ID: 833642

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center